The European Commission has cleared the acquisition of Hospira by Pfizer in phase 1. The clearance is subject to the divestment of some sterile injectable drugs and one biosimilar pipeline.
A CRA team led by Raphaël De Coninck and including Elina Koustoumpardi, Roman Fischer, and Mikaël Hervé advised and provided economic support to Pfizer during the pre-notification and phase 1 proceedings in front of the European Commission.
For more details, please see the Commission’s press release.
R you being foreclosed?
In this article published in the European Competition Journal, Oliver Latham and Chara Tzanetaki draw parallels between the pandemic and foreclosure in network...